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Editors’ NotesArising and Departing
Conventional wisdom dictated that mammals do not generate new neurons after birth, but we now know that several sites in the adult
mammalian nervous system support fairly extensive neurogenesis. However, detecting the actual rates of cell ‘‘birth’’ in these regions
is difficult, partly because of challenges in detecting the origin and lineage of new cells, and also because substantial cell loss occurs
in parallel with growth. These distinct points are addressed by new studies from the Frise´n and Maletic-Savatic laboratories, respec-
tively. In the former, Baranbe´-Heider et al. use genetic fate mapping to demonstrate how discrete cell lineages coordinate to mediateboth homeostasis and responses to injury in the
spinal cord. Sierra et al., on the other hand, monitor
the outcome of cell death in the adult hippocampus,
as well as reveal that microglia phagocytose the
multitude of apoptotic cells in this region and that
they do so without needing to be activated by
inflammatory signals. As Mattocks and Tropepe
discuss in their Preview article, it will be interesting
to explore the possibility that apoptosis and clearing
of cellular debris play an important role in niche-
dependent neurogenesis.Marking the Spot?
The ISSCR section in this issue covers both the annual meeting and a satellite symposium held immediately before it. The caliber and
diversity of findings featured in the Meeting Report by Elefanty et al. emphasize the continuing success of the Society’s annual gath-
ering, and Trounson and colleagues share their take on the discussions that took place at the special workshop held the day before.
In their Committee Forum, the authors outline some of the international policies designed to regulate the clinical application of stem
cell research. They stress the need for coordination between nations in order to establish harmonized oversight that will protect
patients and ensure safe and effective bench-to-bedside translation of basic experimental findings. Policy decisions regarding
how to ensure safe clinical application of pluripotent cell derivatives remain very much under debate. A Letter from Ellis and
colleagues proposes that, from lessons learned from the gene therapy field, autologous iPSCs transferred to patients should carry
geneticmodifications, at least for early trials that will be designed to establish both safety and efficacy of the candidate therapies. This
position diverges from the more common assertion that entirely integration- and mutation-free human iPSCs should be the bench-
mark for clinical-grade purposes. Indeed, Benvenisty and coauthors reveal that the majority of even early-passage pluripotent cell
lines harbor chromosomal abnormalities. Perhaps the inclusion of a known and tested transgenic or PCR-detectable genetic label
will be not only useful for therapeutic analyses, but also essential to allow for quality control and eradication of ‘‘rogue’’ transplanted
cells or progeny.Moving onto Mechanisms
Skeletal muscle can repair itself, somatic cells can be reprogrammed to ESC-like iPSCs, and MSCs can modulate the immune
system. These three statements are relatively accepted tenets from different corners of the stem cell field. However, the specific
molecular mechanisms involved in each case remain largely mysterious. In this issue, Puri and colleagues decode some of the inner
workings that allow skeletal muscle satellite cells to proliferate in response to inflammatory conditions. Interestingly, the authors
connect TNF/stress signaling to polycomb-dependent repression of Pax7, an important muscle stem cell transcription factor that
regulates satellite cell proliferation and differentiation. Regarding human iPSC generation, Li et al. provide evidence that apoptotic
regulators Caspases 3 and 8 are essential during the reprogramming process. Their data reveal that caspases are activated by
Oct-4, and Rb appears to be one of their downstream targets. A third multipotent cell type, MSCs, have already progressedto the point of being utilized in early clinical trials.
Although these cells may function as a source of
replacement cells to mediate tissue repair, at least in
some lineages, the field is also focusing on the capac-
ity of MSCs to modulate immune responses. English
and colleagues summarize how bone marrow-derived
MSCs may facilitate cell and organ transplantation by
outlining the existing mechanistic data of how this
population interacts with and regulates cells of the
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